| Ticker: CGPI | 301 South State Street | |
| Exchange: NASDAQ-National Market | Newtown, Pennsylvania 18940 | |
| Industry: Manufacturing | (215) 579-7388 |
| Type of Shares: | Common Shares | Filing Date: | 4/16/96 | |
| U.S. Shares: | 2,000,000 | Offer Date: | 6/20/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $13.00 - $15.00 | |
| Primary Shares: | 2,000,000 | Offer Price: | $10.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.70 | |
| Offering Amount: | $28,000,000 | Selling: | $0.40 | |
| Expenses: | $500,000 | Reallowance: | $0.10 | |
| Shares Out After: | 7,514,283 |
| Manager | Tier | Phone |
| Alex. Brown & Sons Incorporated | Lead Manager | (410) 727-1700 |
| Volpe, Welty & Company | Co-manager | (415) 956-8120 |
| Auditor: KPMG Peat Marwick | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $5.08 |
| Net Income: | -$6.03 | -$1.72 | -$1.49 | Liabilities: | $1.00 |
| EPS: | -$1.10 | -$0.24 | Equity: | $4.08 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is engaged in the development and commercialization of innovative, proprietary medical therapies for the treatment of periodontal disease and other dental pathologies. The company believes that its initial drug, Periostat, will be the first orally administered, systematically delivered pharmaceutical to treat periodontitis. Unlike existing treatments, which focuses on the bacterial infection associated with periodontitis, Periostat inhibits the chronic progressive tissue degradation characteristic of the disease. The company has completed three pivotal Phase III clinical trials, the company believes that Periostat is a safe, efficacious, cost-effective therapy for the long-term treatment of periodontitis. Due to the costs associated with the disease, the company believes that the treatment of periodontitis will be increasingly important to dental managed care organizations and dental practitioners operating under capitated or fixed free arrangements. |
| Use of Proceeds |
| The proceeds from the offering will be used for marketing expenses associated with new product introduction, the establishment of sales and marketing capabilities, pharmaceutical development, and other general corporate purposes, including working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.